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Hydroxychloroquine and the risk of
respiratory infections among RA
patients
Joel M Kremer ,1 George Reed,2,3 Dimitrios A Pappas,4 LR Harold,5 Kevin Kane,6
Jeffrey Greenberg,7 Kevin Winthrop8
ABSTRACT
Objectives To determine the effect of hydroxychloroquine
on the incidence of new respiratory infections in a large
registry of rheumatoid arthritis (RA) patients compared with
a matched cohort receiving other conventional disease-
modifying antirheumatic drugs (csDMARDs).
Methods We reviewed physician-reported infections
including upper respiratory infections (URI), bronchitis and
pneumonia in the Corrona RA registry from June 2008 to
February 2020 with the goal of comparing infections in
biologic/targeted synthetic (b/ts) DMARDs naive HCQ starts
compared with starts of other csDMARDs and no HCQ.
Patients on different interventions were compared using
time-varying adjusted Cox models adjusting for age, sex,
duration of RA, BMI, disease activity, smoking status,
concurrent medications, season of the year, year of onset
and history of serious infections, diabetes or cardiovascular
disease (CVD). A secondary analysis in a set of propensity-
matched starts were also compared adjusting for time-
varying covariates. The analysis was repeated including URI
and bronchitis only and also for serious respiratory
infections only.
Results No evidence of differences was found in the
incidence of any respiratory infection (URI, bronchitis,
pneumonia) in patients receiving HCQ compared with other
csDMARDs: HR=0.87 (0.70 to1.07) in adjusted analyses and
HR=0.90 (0.70 to 1.17) in adjusted matched analysis.
Similar results were found in the analysis of URI and
bronchitis only and for serious respiratory infections only.
Conclusions In patients with RA, the risk for respiratory
infections was similar among patients using HCQ as
compared to other non-biologic DMARDs.
INTRODUCTION
Because of the recent SARS-CoV-2 pandemic,
there has been speculation in the scientific
and lay press regarding the potential benefit
of either chloroquine or hydroxychloro-
quine (HCQ) in protecting from COVID-19
either by decreasing the incidence, severity
or duration of the infection. A small clinical
study in France was reported to be associated
with diminished viral load,1 while
a subsequent study did not replicate
a positive effect.2 In addition, an in vitro
study has demonstrated that perhaps HCQ
was associated with diminished viral uptake
and replication,3 while a subsequent investi-
gation suggested an effective therapeutic
dose based on in vitro data.4 Non-peer-
reviewed results of small RCTs have conflict-
ing findings.5 6
Perhaps because of these data, there are
now reports of widely diminished availability
of HCQ in pharmacies. Both rheumatoid
arthritis (RA) and systemic lupus erythemato-
sus (SLE) patients have legitimate concerns
associated with difficulty accessing this medi-
cation that they need in order to maintain
disease control. Indeed, pharmaceutical com-
panies have committed to step up their pro-
duction of HCQ given the speculation of
possible benefit and the perception of mini-
mal downside.7
Given the recent speculation regarding the
possible protective effects of HCQ in SARS-
CoV-2 infections8 and the subsequent clinical
questions regarding whether individuals
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► The effect of hydroxychloroquine on the
prevention of viral upper respiratory infections
is not known.
► This study showed that there is no benefit for
prevention of upper respiratory infectionsfor
patients with rheumatoid arthritis on
hydroxychloroquine.
► Given the speculation of the potential anti-viral
effect of hydroxychloroquine for SARS-CoV2,
the finding of an absence of a protective effect
for other respiratory infections suggests that it
would be unlikely if the drug had a specific
protective effect for this virus if the effect
does not exist for other viral infections in this
population.
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currently using HCQ have a lower risk of such infections,
understanding the baseline risk of respiratory infections
in general among HCQ users is of utmost relevance and
importance. The understanding of the effects of HCQ on
routine community-acquired viral infections will be infor-
mative as the drug is investigated for a possible protective
effect on COVID-19 in a population-based fashion. It is
also reasonable to hypothesise that if there is
a measurable HCQ antiviral effect then patients on
chronic therapy with the drug may experience less fre-
quent respiratory infections typically caused by viruses.
Accordingly, we chose to use the Corrona registry to
evaluate the risk of respiratory infections among HCQ




The Corrona RA registry, collecting data since 2001,
includes data derived from a network of academic
(13%) and community rheumatologists (87%) as has
previously been described.9 All patients are consented
for participation using the New England Institutional
Review Board. Data are gathered at clinical visits from
both the patient and the treating provider including
detailed safety and treatment information. As part of the
routine data collected at the time of a clinical encounter,
the registry mandates active collection of safety data
including both historical and contemporaneous informa-
tion on infections including upper respiratory infections
(URIs), bronchitis and pneumonia. The type of infection
is collected including whether intravenous antibiotics
were administered and whether the infection led to hos-
pitalisation, recovery or death. For this analysis, the first
start ofHCQby a patient was included and the first start of
other csDMARDs by a patient was included if they
occurred after June 2008 since the specific indicator for
bronchitis was added at that time. Patients could contri-
bute more than one start but not of the same csDMARD.
Patients did not have to beHCQnaïve or other csDMARD
naïve at the time of the start of the csDMARD. All eligible
starts had to occur in b/tsDMARD naïve RA patients and
have at least one month of follow-up after the start. If the
order of a start and an outcome of interest were indeter-
minate, the start was excluded from analysis.
Eligible medication starts were divided into two
cohorts: the hydroxychloroquine (HCQ) cohort and
csDMARD cohort (with no HCQ use) (figure 1).
Outcomes
Safety data, including infections, are collected at the time
of the registry visit and include all interval occurrences
since the prior registry visit. The primary outcome was the
combined incidence of URI, bronchitis and pneumonia.
Secondary outcomes were the combined incidence of
URI and bronchitis and the incidence of serious respira-
tory infections (URIs, bronchitis and pneumonia only).
Serious infections are cases that led to hospitalisation or
needing intravenous antibiotics for therapy. Incident
infections and the date of the infection (month/year)
are captured on the physician (MD) form at the time of
a registry visit when patients are also specifically ques-
tioned about infections that may have occurred in the
interim period between visits. Serious infections are also
captured by targeted adverse event (TAE) forms between
clinical visits. MD form and TAE reported serious infec-
tions are combined and assessed to avoid duplicate
reporting of serious infections.
Exposure time
The HCQ cohort consisted of HCQ starts possibly added
to other csDMARDs but without simultaneous concurrent
csDMARDs starts. Follow-up (exposure time) continued
until the occurrence of either of the following events:
► Respiratory infection of interest (URI, bronchitis,
pneumonia; URI, bronchitis; serious infection).
► Discontinuation of HCQ +30 days.
► Start of a b/tsDMARD +30 days.
The csDMARD cohort consisted of non-HCQ
csDMARD starts. Follow-up time continued until the ear-
liest of these events:
► Respiratory infection of interest (URI, bronchitis,
pneumonia; URI, bronchitis; serious infection).
► Discontinuation of the index csDMARD +30 days.
► Start of a b/tsDMARD +30 days.
► Start of HCQ.
Patients could contributemore than one start but could
only contribute one start for any single csDMARD (eg,
a patient could contribute one HCQ start, one MTX start
and one leflunomide start)
Analysis
Comparison of patient and clinical characteristics at the
index date—start of HCQ or non-HCQ csDMARD—were
compared using t-test for continuous variables and χ2 test
for categorical variables.
Figure 1 Starts included based on eligibility.
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Unadjusted Kaplan-Meier curves were estimated for the
HCQ and csDMARD cohorts. Cox regression models esti-
mated HRs (hazard of respiratory infection in HCQ star-
ters vs csDMARD starters) adjusted for a priori selected
baseline characteristics (sex, age, duration of RA, body
mass index (BMI), year of start, history of serious infec-
tions) and time-varying covariates (disease activity as mea-
sured by the Clinical Disease Activity Index (CDAI)), prior
use of 1 versus 2 or more csDMARDs, use of prednisone
and its dose, season of the year, history of diabetes and
history of cardiovascular disease (CVD). Time-varying cov-
ariates were updated at each Corrona clinical visit. Covar-
iance estimates were adjusted for clustering by patient
(some patients contribute more than one start).8 Propor-
tional hazard assumptions were tested and not rejected.
Values in the manuscript are presented as mean(SD).
A secondary sensitivity analysis was carried out using
a population of matched HCQ starters with csDMARD
starters. A propensity for HCQ start versus csDMARD start
score was estimated using a logistic regression model
using the following selected variables: gender, age,
CDAI, prednisone use, duration of RA, number of
csDMARDs at start, history of serious infections, diabetes
mellitus, CVD and BMI. HCQ starts were matched 1:1
with csDMARD starts with a caliper of 0.01. Unadjusted
Kaplan-Meier curves were estimated in the matched
populations and a Cox regression model estimated the
HR of risk of infection in HCQ to csDMARD matched
starters using time-varying covariates and a covariance
estimate adjusted for clustering by pair.
The analyses were repeated for all three outcomes.
RESULTS
Figure 1 illustrates the starts included based on eligibility.
For the primary analysis of URI, Bronchitis and Pneumo-
nia as the outcome, there were a total of 6792 starts from
5726 patients. There were 2270 starts of HCQ, and 4422
starts of csDMARDs other than HCQ (2903 starts on
MTX, 965 on leflunomide, 600 on azulfidine, 35 on
azathioprine, 18 on minocycline and 1 ciclosporin).
Since the total starts were depending on the outcome
considered (see figure 1), counts differed slightly for
the two other outcomes. In the matched starts for the
primary outcome, there were 1534 HCQ starts and 1534
csDMARD starts (831 MTX, 385 leflunomide, 290 azulfi-
dine, 16 azathioprine, 11 minocycline and 1 ciclosporin).
At baseline, disease activity was greater in patients on non-
HCQ csDMARDs (clinical disease activity index (CDAI)
of 17.2 (13.8) and 12.7 (10.8) respectively, p<00183.001).
A prior history of serious infection was more common in
patients on HCQ than those on the other csDMARDs
(p=0.041) (table 1). A significantly greater percentage
of patients were on >7.5 mg of prednisone at the time of
start in the csDMARD cohort versus HCQ (14.1% vs 7.3%,
respectively, p<0.001) but a greater number of HCQ
patients were on 2 or more csDMARDs at the time of
start compared with the other cohort (52.3% vs 14.2%,
respectively, p<0.001). None of these differences
remained significant after matching (table 1). The num-
ber of starts were a little higher (20–30 additional starts)
for the secondary outcomes since there were fewer events
and thus fewer exclusions (figure 1). Similar differences
existed for secondary outcomes with no differences in the
matched cohorts.
There were 543 respiratory infections of which 234 were
reported as URI, 184 as bronchitis and 125 as pneumonia.
Table 2 lists estimates of overall rates of respiratory infec-
tions per 100 patient-years and by cohort. The estimated
HRsand 95% CIs comparing risk in HCQ versus
csDMARD starts of combined URI, bronchitis and pneu-
monia; combined URI and bronchitis; and serious infec-
tions are provided in table 2. While the HR estimates are
slightly less than 1, CIs extend for most estimates
above 1.1.
The HR comparing risk in HCQ versus csDMARD was
0.87 (0.70, 1.07) and 0.90 (0.70, 1.17) for the total respira-
tory infections of URI, bronchitis and pneumonia from
the adjustedmodel for all starters and the adjustedmodel
for matched starters, respectively. HR estimates and CIs
were similar when comparing only URI and bronchitis as
the outcomes (adjusted HR of 0.85 (0.68 to1.08) and 0.93
(0.70 to 1.25) for all starters andmatched starters, respec-
tively) or when comparing serious respiratory infections
HR of 1.29 (0.76 to 2.18) and 1.10 (0.58 to 2.12) (table 2).
In the matched starters, a Kaplan-Meier curve for the
primary outcome ofURI, bronchitis and pneumonia illus-
trates overlapping proportion with no infection (unad-
justed for time-varying covariates) (figure 2).
DISCUSSION
In summary, we found little evidence to suggest that the
use of HCQ, compared with patients not on the drug but
on csDMARDs, was associated with a diminished inci-
dence of common, typically viral, respiratory infections.
Results were consistent based on adjusted multivariable
models and matched analysis across the three outcomes
analysed. To our knowledge, this is the only study that
examined the incidence of infections in a large number
of patients receiving chronic HCQ treatment over pro-
longed treatment intervals compared with patients on
other csDMARDs in the setting of a rheumatic disease.
HCQ antimicrobial effectiveness has been speculated
to be present mainly against viruses like SARS-CoV-2 but
also against parasites and intracellular bacteria.10–13
Although the vast majority of URIs are viral, there are
likely some bacterial infections in the pneumonia data we
report. This is the reason we separately examined the
rates of URIs and bronchitis that are typically viral
(excluding pneumonias that can be viral as well as pri-
marily or secondarily bacterial).
Beyond the antiviral HCQ properties which may
be responsible for a potential favourable effect on
COVID-19, it has been speculated that the immunomo-
dulatory effects of HCQ may interfere with the evolution
Rheumatoid arthritis
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of the cytokine storm which is considered to be respon-
sible for the progression to a more serious infection.14 15
Our secondary analysis focusing only on serious respira-
tory infection did not identify a protective signal for ser-
ious infections in patients on HCQ.
The absence of any signal indicating that HCQ could
indeed be associated with a diminished rate of these
infections is potentially relevant to the present healthcare
environment. Of course, it is unknown whether the
dynamics of HCQ interaction with the many viruses that
cause common URIs, bronchitis or pneumonia are
indeed representative of its effect on the SARS-CoV-2
virus. HCQ and chloroquine do have in vitro activity
against SARS-CoV-2 and a number of other respiratory
viruses. Despite this, prior human studies in Dengue,
influenza A and other RNA viral infections have failed
to find protective effects for these compounds.12 16 17 In
vitro, HCQ has recently been shown to be 3χ more active
than chloroquine against SARS-CoV-2 virus.4 There are
limited human data as to whether this antiviral effect is
present in humans.1 2 5 6
It is of note that prior to matching, patients receiving
HCQ monotherapy had less active disease (table 1) than
patients on other csDMARDs (clinical disease activity
index (CDAI) 12.7 vs 17.5, p<0.001, respectively). In addi-
tion, it would be expected that patients on the csDMARDs
MTX and leflunomide (56.9% of total csDMARDs prior
to matching) would have a greater susceptibility to infec-
tions due to possible immunosuppression from these
agents not seen with HCQ. In spite of these differences
Table 1 Baseline characteristics of patients starting hydroxychloroquine and other csDMARD* medications at time of start of
drug for all starters and in the matched cohort









Mean (SD) Mean (SD) Std. Diff.† Mean (SD) Mean (SD) Std. Diff.
Age 60.05 (13.99) 60.38 (13.44) 0.084 60.11 (14.30) 59.97 (13.69) 0.010
Duration of RA‡ 5.66±8.00 5.45±8.36 0.025 5.5±8.27 5.51±7.77 0.002
CDAI§ 12.7±10.80 17.15±13.77 0.359 13.38±11.24 13.54±11.37 0.014
BMI 29.53±6.96 29.84±6.94 0.045 29.54±6.96 29.77±7.03 0.033
N(%) N(%) N(%) N(%)
Gender 0.077 0.012
Men 523 (23.2) 1193 (26.5) 368 (24) 360 (23.5)
Women 1730 (76.8) 3303 (73.5) 1166 (76) 1174 (76.5)
Hx of CVD 311 (13.7) 563 (12.5) 0.037 212 (13.8) 216 (14.1) 0.008
Hx of Diabetes 228 (10) 495 (10.9) 0.029 156 (10.2) 162 (10.6) 0.013
Smoking Status 0.004 0.011
Never 1146 (51.1) 2256 (50.6) 795 (52.2) 783 (51.3)
Previous 723 (32.3) 1478 (33.1) 478 (31.4) 491 (32.2)




None 1665 (74) 3040 (68.4) 1112 (72.5) 1113 (72.6)
<7.5 mg 421 (18.7) 780 (17.5) 278 (18.1) 289 (18.8)




One 1083 (47.7) 3878 (85.8) 973 (63.4) 989 (64.5)
2+ 1187 (52.3) 644 (14.2) 561 (36.6) 545 (35.5)
Hx of Serious
Infection¶
156 (6.9) 254 (5.6) 0.052 105 (6.8) 97 (6.3) 0.021
*csDMARD medications refers to conventional disease-modifying antirheumatic drugs.
†Std. Diff. is the standardised difference between the two treatment groups.
‡Duration of RA refers to duration of rheumatoid arthritis since initial diagnosis.
§CDAI refers to Clinical Disease Activity Index-a clinical measurement of RA disease severity.
¶Hx of Serious Infection refers to history of serious upper respiratory infection, bronchitis or pneumonia prior to starting hydroxychloroquine or
csDMARD medication.
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that could bias towards less infection in patients on HCQ,
we did not observe this effect.
Our approach has several strengths. We examined
results both in the larger population of all starters with
statistical adjustment and alternatively in a matched
population with similar results. To our knowledge, this
study is the only examination of the possible real-world
protective effects of HCQ for common respiratory infec-
tions. Our study was conducted in a large population over
a prolonged period of observation with systematic record-
ing of all infections including those that occurred in the
interval between visits as well as at the time of the clinical
evaluation with simultaneous evaluation of important
covariates such as other comorbidities and disease
activity.
There are several limitations to this study. We studied
patients with RA and it is possible that the effect of HCQ in
this populationmay not be applicable to the general popu-
lation who are susceptible to SARS-CoV-2. The mean age
(60 years old) of the patients in the Corrona registry is
perhaps greater than the mean age in the general popula-
tion susceptible to this infection although the virus is of
course more virulent in the older population represented
in this registry. The secondary analysis of serious infections
had limited number of events (n=80). It is important to
note that the process of recording of respiratory infections
at the time of a Corrona encounter did not allow for the
possible identification of a more mild or shorter duration
of infection than might have occurred if the patient was
not on HCQ. It is therefore not possible to rule out
Table 2 Estimated rates of respiratory infections and estimated HRs comparing risk of infection in hydroxychloroquine
compared to csDMARD* (without hydroxychloroquine use)
URI, bronchitis, pneumonia
Rates of infection n Patient-years (PY) Rate/100 PY
Hydroxychloroquine 198 2872 6.9
csDMARD 345 4851 7.1
Total 543 7722 7.0
HRs Model All Starters Matched










Rates of infection n PY Rate/100 PY
Hydroxychloroquine 157 2915 5.4
csDMARD 269 4904 5.5
Total 426 7819 5.4
HRs Model All Starters Matched









Serious infections (URI, Bronchitis, Pneumonia)
Rates of infection n PY Rate/100 PY
Hydroxychloroquine 32 3062 1.04
csDMARD 48 5123 0.94
Total 80 8186 0.98
HRs Model All Starters Matched









*csDMARD medications refers to conventional disease-modifying antirheumatic drugs.
†Cox regressionmodels adjusted for baseline characteristics and time-varying covariates including disease activity as measured by the Clinical
Disease Activity Index (CDAI), prior use of 1 versus 2 or more csDMARDs, use of prednisone and its dose, season of the year, history of diabetes
and history of cardiovascular disease.
Rheumatoid arthritis


















pen: first published as 10.1136/rm






a possible salutary effect of HCQ on the intensity or dura-
tion of viral symptoms. In addition, because we found no
effect of HCQ on these infections in our database does not
rule out the possibility that HCQ could be effective for the
SARS-CoV-19 virus. Finally, it is possible that some infec-
tions were missed, not reported or forgotten at the time of
the clinic visit when the Corrona forms were completed.
Nevertheless, we believe that it is unlikely that the distribu-
tion of possible under-reporting would be skewed between
the cohorts studied.
It is clear that this observational study should not be
considered definitive as only an appropriately powered,
prospective intervention of hydroxychloroquine in
a controlled trial of patients with newly diagnosed SARS-
CoV-2 infection can provide reliable evidence. HCQ does
not appear to decrease the risk of viral infections when
compared to csDMARDs.
In summary, we found little evidence in a large number
of patients with RA on HCQ that there was a diminution
in respiratory infections including URIs, bronchitis or
pneumonia. It is acknowledged that this experience may
not necessarily be relevant to the effect of HCQ on SARS-
CoV-2. The effects of HCQ in patients with SARS-CoV-2
virus and COVID-19 infection should be studied in RCTs
and later population-based fashion to determine if the
in vitro and small blinded studies are indicative of its
clinical effects in this infection. Understanding how
HCQ contributes to risk in other viral infections, and
respiratory infections in general, is useful as it will help
inform these future investigations. It should be noted that
the evidence we describe would not support the diversion
of limited supplies of HCQ to the adjunctive treatment of
viral syndromes in general given the reports of the chal-
lenges that many patients with both RA and SLE are
having in accessing this drug needed for their routine
care and well-being.
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Figure 2 Kaplan-Meier curve for the primary outcome of URI, bronchitis and pneumonia.
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